(Q36214515)

English

Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Amita Datta-Mannan

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Arunkumar Thangaraju

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Donmienne Leung

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Ying Tang

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Derrick R Witcher

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Jirong Lu

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Victor J Wroblewski

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

publication date

1 January 2015

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Monoclonal Antibodies

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

483-493

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

1 October 2017

Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

1 October 2017

Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

1 October 2017

Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

1 October 2017

Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

1 October 2017

Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

1 October 2017

FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

1 October 2017

Off-target platelet activation in macaques unique to a therapeutic monoclonal antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

1 October 2017

Therapeutic antibodies: market considerations, disease targets and bioprocessing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

1 October 2017

Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

1 October 2017

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

1 October 2017

Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

1 October 2017

Ligand valency affects transcytosis, recycling and intracellular trafficking mediated by the neonatal Fc receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

1 October 2017

Elimination mechanisms of therapeutic monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

1 October 2017

The sweet and sour of cancer: glycans as novel therapeutic targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

1 October 2017

Functions of cell surface heparan sulfate proteoglycans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

1 October 2017

A strategy for risk mitigation of antibodies with fast clearance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

22 September 2018

Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

22 September 2018

Reduced elimination of IgG antibodies by engineering the variable region.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

22 September 2018

Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

22 September 2018

Underlying mechanisms of pharmacology and toxicity of a novel PPAR agonist revealed using rodent and canine hepatocytes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

22 September 2018

Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

22 September 2018

An engineered human IgG1 antibody with longer serum half-life.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4622971

22 September 2018

Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization

1 reference

https://api.crossref.org/works/10.1080%2F19420862.2015.1016696

21 January 2018

Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences

1 reference

https://pubmed.ncbi.nlm.nih.gov/25695748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1080/19420862.2015.1016696

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36214515&oldid=1988866763"